I now have comprehensive information to give a thorough answer.
Bartter Syndrome
Bartter syndrome is a group of autosomal recessive renal tubular disorders defined by impaired salt reabsorption in the thick ascending limb (TAL) of the loop of Henle. The net result mimics chronic loop diuretic administration: hypokalemia, hypochloremic metabolic alkalosis, hyperreninemia, hyperaldosteronism, and normal-to-low blood pressure.
- Brenner and Rector's The Kidney, 2-Volume Set, p. 3151
- NKF Primer on Kidney Diseases, 8e, p. 176
Pathophysiology
The TAL normally reabsorbs ~25-30% of filtered NaCl without water, generating the medullary concentration gradient. Four key transport proteins accomplish this:
Loss of function in any of these proteins eliminates the lumen-positive transepithelial voltage, abolishes paracellular reabsorption of Na+, Ca2+, and Mg2+, and causes salt wasting. The resulting volume depletion activates the renin-angiotensin-aldosterone system (RAAS), delivering excess NaCl to the collecting tubule, where Na+ reabsorption drives K+ and H+ secretion - producing hypokalemia and metabolic alkalosis.
Additionally, defective chloride reabsorption at the macula densa impairs tubuloglomerular feedback (TGF) and activates COX-2, which upregulates prostaglandin E2 (PGE2), causing afferent arteriolar dilation, further hyperreninism, and polyuria.
Genetic Classification (Types 1-6)
| Type | Gene | Protein | Key Features |
|---|
| 1 | SLC12A1 | NKCC2 (apical Na-K-2Cl cotransporter) | Antenatal; polyhydramnios, nephrocalcinosis |
| 2 | KCNJ1 | ROMK (apical K+ channel) | Antenatal; paradoxical neonatal hyperkalemia (resolves in days-weeks) |
| 3 | CLCNKB | ClC-Kb (basolateral Cl- channel) | Classic postnatal; mildest; rarely nephrocalcinosis; can mimic Gitelman |
| 4a | BSND | Barttin (subunit for ClC-Ka + ClC-Kb) | Antenatal + sensorineural deafness; linked to chr 1p31 |
| 4b | CLCNKA + CLCNKB | Both ClC-Ka and ClC-Kb | Severe antenatal; deafness |
| 5 | CASR (gain-of-function) | Calcium-sensing receptor | Autosomal dominant hypocalcemia phenotype; CaSR inhibits ROMK |
| 6 | MAGED2 | MAGE-D2 (regulatory) | Transient antenatal form; resolves completely by 3-4 weeks of life; X-linked |
Types 1, 2, and 4 typically present antenatally (most severe); type 3 presents classically in childhood; types 5 and 6 are rarer variants.
Clinical Features
Antenatal / Neonatal Bartter
- Maternal polyhydramnios (fetal polyuria)
- Premature birth
- Postnatal: severe polyuria, vomiting, failure to thrive
- Hypercalciuria and nephrocalcinosis (especially types 1, 2, 4)
- Marked electrolyte wasting: hypokalemia, metabolic alkalosis
- Type 4: add sensorineural deafness
- Type 2 neonates: paradoxical hyperkalemia initially (ROMK also mediates K+ secretion in collecting duct; other channels compensate within the first week)
Classic (Postnatal) Bartter - predominantly Type 3
- Failure to thrive, polyuria, polydipsia
- Hypokalemic, hypochloremic metabolic alkalosis
- Normal to low blood pressure despite elevated renin/aldosterone
- Vascular resistance to angiotensin II
- ~20% hypomagnesemia
- Often hypercalciuria (but less than antenatal form)
- Additional findings: growth hormone deficiency, hypophosphatemia with renal phosphate wasting, hyperparathyroidism
Distinguishing Bartter from Gitelman Syndrome
| Feature | Bartter | Gitelman |
|---|
| Defective segment | TAL (loop of Henle) | DCT (distal convoluted tubule) |
| Affected protein | NKCC2, ROMK, ClC-Kb, Barttin | NCC (thiazide-sensitive cotransporter) |
| Mimics | Loop diuretics | Thiazide diuretics |
| Onset | Antenatal or childhood | Late childhood / adulthood |
| Calcium | Hypercalciuria, nephrocalcinosis | Hypocalciuria |
| Magnesium | Normal (or mild hypomagnesemia) | Hypomagnesemia (prominent) |
| Severity | More severe | Milder; salt craving, cramps, fatigue |
The urine chloride is elevated in Bartter syndrome (distinguishing it from surreptitious vomiting, where urine Cl- is low).
Diagnosis
- Biochemistry: hypokalemia, metabolic alkalosis, elevated plasma renin and aldosterone, normal-to-low blood pressure
- Urine: elevated Cl-, often hypercalciuria
- Exclude: surreptitious vomiting (low urine Cl-), diuretic abuse (urine diuretic screen), laxative abuse
- Genetic testing: confirms subtype
- Kidney ultrasound: may show nephrocalcinosis in antenatal types
Treatment
Treatment is supportive and does not correct the underlying tubular defect. Goals are to minimize hypokalemia and electrolyte losses.
- Salt and potassium supplementation - mainstay; IV saline in severely affected neonates
- Indomethacin (COX inhibitor) - reduces PGE2, improves polyuria, raises K+, decreases renin activity; especially useful in antenatal/neonatal forms. Risk of necrotizing enterocolitis and bowel perforation in neonates.
- Selective COX-2 inhibitors (rofecoxib, celecoxib) - proposed as alternatives with lower GI risk, though cardiovascular safety concerns exist with long-term use
- Potassium-sparing diuretics (amiloride, spironolactone, eplerenone) - help correct hypokalemia but worsen salt wasting; use with great caution, especially in infants
- ACE inhibitors / propranolol - reduce aldosterone-driven K+ losses
- Magnesium supplementation - when hypomagnesemia is present
Key Points
- Bartter syndrome = "loop diuretic in a gene" - loss of TAL salt reabsorption
- Always consider if a patient has persistent hypokalemic metabolic alkalosis + normal/low BP + elevated renin/aldosterone
- Type 4 = deafness (barttin mutation)
- Type 2 = paradoxical neonatal hyperkalemia
- Type 6 (MAGED2) = transient (resolves spontaneously)
- Prostaglandins amplify the phenotype - COX inhibition is a cornerstone of therapy in severe forms
- Gitelman vs. Bartter: calcium is the key discriminator (hypercalciuria vs. hypocalciuria)
Recent literature (2023 systematic review of case reports,
PMID 37763757) continues to highlight phenotypic variability across subtypes and underscores the value of genetic confirmation.